What kind of medicine does osimertinib/osimertinib belong to?

Osimertinib (Osimertinib) is a targeted therapy drug that is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is mainly used to treat EGFR gene mutation-positive non-small cell lung cancer (NSCLC), especially patients who are resistant to other EGFR inhibitors. The following is a more detailed introduction about osimertinib/osimertinib:

1.Targeted therapy drugs:Osimertinib/Osimertinib is a targeted therapy drug. Its mechanism of action is to block the growth and spread of tumor cells by specifically inhibiting the EGFR pathway. Compared with traditional chemotherapy drugs, targeted drugs act on tumor cells more accurately, reduce damage to normal cells, and improve the effectiveness of treatment.

2.EGFRTyrosine kinase inhibitor:EGFR is a receptor tyrosine kinase located on the cell membrane, which is involved in regulating important physiological processes such as cell growth, proliferation and survival. Osimertinib/Osimertinibas an EGFRtyrosine kinase inhibitor, it can inhibit the activity of EGFR and block the signal transduction pathway, thereby inhibiting the proliferation and metastasis of tumor cells.

3.Drugs targeting specific gene mutations:Osimertinib/OsimertinibMainly used for treatmentEGFRgene mutation-positive NSCLC patients, especially those who are resistant to first- and second-generation EGFR inhibitors. EGFRmutations are one of the most common markers for targeted therapy in NSCLC, and osimertinib/osimertinibIt has shown significant efficacy in both first-line and second-line treatments.

4.Targeted drugs to overcome drug resistance: During NSCLC treatment, patients may develop resistance to other EGFR inhibitors. One of the common resistance mutations is the EGFR T790M mutation. Osimertinib/Osimertinib has high selectivity, especially targeting the EGFR T790M mutation, and can overcome the resistance of other EGFR inhibitors, thereby prolonging the survival time of patients and improving the therapeutic effect.

In general, Osimertinib/Osimertinib is a targeted therapy drug that acts on the EGFR pathway and is mainly used for treatmentEGFRgene mutation-positive NSCLC patients, especially those who are resistant to other EGFR inhibitors. It is an innovative drug that brings new treatment options to patients with NSCLC and has achieved remarkable results in clinical practice.